Urinary APE1/Ref-1: A Potential Bladder Cancer Biomarker
Urinary APE1/Ref-1: A Potential Bladder Cancer Biomarker
复制标题
DOI：
10.1155/2016/7276502
复制
发表时间：
2016-01-01
期刊：
影响因子：
--
通讯作者：
Jeon, Byeong Hwa
中科院分区：
文献类型：
--
作者：
Choi, Sunga;Shin, Ju Hyun;Jeon, Byeong Hwa
膀胱癌（BCa）是最常见的尿路上皮癌之一，其发病率至今仍不容忽视. BCa的早期检测与成功的治疗结果高度相关。我们先前表明，脱嘌呤/脱嘧啶核酸内切酶1/氧化还原因子-1（APE 1/Ref-1）在BCa患者血清中的表达水平高于健康对照组。在这项研究中，我们调查了BCa患者的尿APE 1/Ref-1是否也升高。在这项病例对照研究中，收集了277例受试者的排尿，包括169例BCa患者和108例非BCa对照。采用酶联免疫吸附试验（ELISA）检测尿APE 1/Ref-1水平。BCa患者的APE 1/Ref-1水平相对于非BCa对照组显著升高，并与肿瘤分级和分期相关。有BCa复发史的患者尿APE 1/Ref-1水平也较高。APE 1/Ref-1的受试者工作特征（ROC）曲线显示曲线下面积为0.83，表明该生物标志物的可靠性和有效性。在0.376 ng/100 μ L的临界值下，检测尿液中APE 1/Ref-1的灵敏度和特异性的最佳组合被确定为82%和80%。总之，从非侵入性获得的体液中测量的尿APE 1/Ref-1水平将在临床上适用于BCa的诊断。
Bladder cancer (BCa) is one of the most common urothelial cancers with still noticeable incidence rate. Early detection of BCa is highly correlated with successful therapeutic outcomes. We previously showed that apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) was expressed at an increased level in the serum of BCa patients when compared to the level in healthy controls. In this study, we investigated whether urinary APE1/Ref-1 was also elevated in patients with BCa. In this case-control study, voided urine was collected from 277 subjects including 169 BCa patients and 108 non-BCa controls. Urinary APE1/Ref-1 level was assessed by enzyme-linked immunosorbent assay (ELISA). APE1/Ref-1 levels were significantly elevated in BCa patients relative to levels in non-BCa controls and were correlated with tumor grade and stage. Urinary APE1/Ref-1 levels were also higher in patients with recurrence history of BCa. The receiver operating characteristics (ROC) curve of APE1/Ref-1 showed an area under the curve of 0.83, indicating the reliability and validity of this biomarker. The optimal combination of sensitivity and specificity was determined to be 82% and 80% at a cut-off value of 0.376 ng/100 mu L for detection of APE1/Ref-1 in urine. In conclusion, urinary APE1/Ref-1 levels measured from noninvasively obtained body fluids would be clinically applicable for diagnosis of BCa.